These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 27266754)

  • 21. 90Y-Ibritumomab Tiuxetan consolidation after autologous stem cell transplantation improves survival of patients with intermediate-/high-risk diffuse large B-cell lymphoma not responding adequately to first-line treatment.
    Mondello P; Pitini V; Arrigo C; Derenzini E; Mian M
    Anticancer Res; 2014 Sep; 34(9):5121-5. PubMed ID: 25202102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial.
    Fayad L; Ansell SM; Advani R; Coiffier B; Stuart R; Bartlett NL; Forero-Torres A; Kuliczkowski K; Belada D; Ng E; Drachman JG
    Leuk Lymphoma; 2015; 56(9):2569-78. PubMed ID: 25651427
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maintenance rituximab following induction R-CHOP chemotherapy in patients with composite or discordant, indolent and aggressive, B-cell non-Hodgkin lymphomas.
    Kansara R; Connors JM; Savage KJ; Gerrie AS; Scott DW; Slack GW; Gascoyne RD; Sehn LH; Villa D
    Haematologica; 2016 Oct; 101(10):e411-e414. PubMed ID: 27479818
    [No Abstract]   [Full Text] [Related]  

  • 24. Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab.
    Papageorgiou SG; Diamantopoulos P; Levidou G; Angelopoulou MK; Economopoulou P; Efthimiou A; Constantinou N; Katsigiannis A; Korkolopoulou P; Pappa V; Economopoulou C; Georgiou G; Dimou M; Tsirigotis P; Kyrtsonis MC; Kotsianidis I; Kalpadakis C; Dimopoulos MA; Beris P; Meletis J; Pangalis GA; Dervenoulas J; Panayiotidis P; Vassilakopoulos TP
    Hematol Oncol; 2013 Mar; 31(1):10-7. PubMed ID: 22610484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma.
    Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
    Leuk Lymphoma; 2006 Aug; 47(8):1545-52. PubMed ID: 16966265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort.
    Alinari L; Gru A; Quinion C; Huang Y; Lozanski A; Lozanski G; Poston J; Venkataraman G; Oak E; Kreisel F; Park SI; Matthews S; Abramson JS; Iris Lim H; Martin P; Cohen JB; Evens A; Al-Mansour Z; Singavi A; Fenske TS; Blum KA
    Am J Hematol; 2016 Jun; 91(4):395-9. PubMed ID: 26800311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effective immunochemotherapy for aggressive non-Hodgkin's lymphoma.
    Coiffier B
    Semin Oncol; 2004 Feb; 31(1 Suppl 2):7-11. PubMed ID: 15042528
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography.
    Pinnix CC; Dabaja B; Ahmed MA; Chuang HH; Costelloe C; Wogan CF; Reed V; Romaguera JE; Neelapu S; Oki Y; Rodriguez MA; Fayad L; Hagemeister FB; Nastoupil L; Turturro F; Fowler N; Fanale MA; Nieto Y; Khouri IF; Ahmed S; Medeiros LJ; Davis RE; Westin J
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):113-21. PubMed ID: 25863759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
    Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
    Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Post-autologous stem cell transplantation administration of rituximab improves the outcome of patients with aggressive B cell non-Hodgkin's lymphoma.
    Tsirigotis P; Dray L; Resnick IB; Ackerstein A; Gesundheit B; Elad S; Or R; Shapira MY
    Ann Hematol; 2010 Mar; 89(3):263-72. PubMed ID: 19693502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
    Kewalramani T; Zelenetz AD; Nimer SD; Portlock C; Straus D; Noy A; O'Connor O; Filippa DA; Teruya-Feldstein J; Gencarelli A; Qin J; Waxman A; Yahalom J; Moskowitz CH
    Blood; 2004 May; 103(10):3684-8. PubMed ID: 14739217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas.
    Cortelazzo S; Tarella C; Gianni AM; Ladetto M; Barbui AM; Rossi A; Gritti G; Corradini P; Di Nicola M; Patti C; Mulé A; Zanni M; Zoli V; Billio A; Piccin A; Negri G; Castellino C; Di Raimondo F; Ferreri AJ; Benedetti F; La Nasa G; Gini G; Trentin L; Frezzato M; Flenghi L; Falorio S; Chilosi M; Bruna R; Tabanelli V; Pileri S; Masciulli A; Delaini F; Boschini C; Rambaldi A
    J Clin Oncol; 2016 Nov; 34(33):4015-4022. PubMed ID: 28199143
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
    Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autologous and allogeneic stem cell transplantation: rising therapeutic promise for mantle cell lymphoma.
    Tam CS; Khouri IF
    Leuk Lymphoma; 2009 Aug; 50(8):1239-48. PubMed ID: 19562639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and toxicity of PACEBOM chemotherapy in relapsed/refractory aggressive lymphoma in the rituximab era.
    Tamjid B; Mckendrick J; Schwarer A; Doig R; James P; Hosking P; Hawkes EA
    Asia Pac J Clin Oncol; 2017 Jun; 13(3):226-233. PubMed ID: 28004881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
    Zimmermann H; Reinke P; Neuhaus R; Lehmkuhl H; Oertel S; Atta J; Planker M; Gärtner B; Lenze D; Anagnostopoulos I; Riess H; Trappe RU
    Cancer; 2012 Oct; 118(19):4715-24. PubMed ID: 22392525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A retrospective analysis of outcomes for primary mediastinal large B-cell lymphoma treated with RCHOP followed by radiotherapy or front-line autologous stem cell transplantation.
    Liu X; Deng T; Guo X; Guo Y; Wang L; Zhang J; Xia Z; Zhang Q; Xue K; Cao J; Shi J; Hong X
    Hematology; 2017 Jun; 22(5):258-264. PubMed ID: 27884092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Upfront autologous stem cell transplantation for untreated high-risk diffuse large B-cell lymphoma in patients up to 60 years of age.
    Takasaki H; Hashimoto C; Fujita A; Matsumoto K; Taguchi J; Kuwabara H; Yamazaki E; Koharazawa H; Fujita H; Fujisawa S; Ishii Y; Yamamoto W; Motomura S; Tomita N; Ishigatsubo Y; Sakai R
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):404-9. PubMed ID: 23763919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma.
    Till BG; Gooley TA; Crawford N; Gopal AK; Maloney DG; Petersdorf SH; Pagel JM; Holmberg L; Bensinger W; Press OW
    Leuk Lymphoma; 2008 Jun; 49(6):1062-73. PubMed ID: 18452065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era.
    Sesques P; Bourcier J; Golfier C; Lebras L; Nicolas-Virelizier E; Hacini M; Perrin MC; Voillat L; Bachy E; Traverse-Glehen A; Moreau A; Martin L; Ramla S; Casasnovas O; Le Gouill S; Salles G; Ghesquières H
    Hematol Oncol; 2020 Apr; 38(2):137-145. PubMed ID: 31953963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.